ZyVersa Therapeutics (ZVSA) Projected to Post Quarterly Earnings on Wednesday

ZyVersa Therapeutics (NASDAQ:ZVSA) is expected to post its Q4 2025 resultson Wednesday, April 1st. Analysts expect ZyVersa Therapeutics to post earnings of ($0.30) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, April 2, 2026 at 9:30 AM ET.

ZyVersa Therapeutics Stock Down 0.9%

Shares of NASDAQ:ZVSA opened at $0.22 on Wednesday. The company has a market cap of $1.75 million, a price-to-earnings ratio of -0.16 and a beta of 0.66. The business has a 50 day moving average price of $0.22 and a 200 day moving average price of $0.17. ZyVersa Therapeutics has a twelve month low of $0.11 and a twelve month high of $1.94.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.